Skip to main content
Erschienen in: Cancer Immunology, Immunotherapy 1/2018

11.09.2017 | Original Article

Tumor infiltrating lymphocytes in lymph node metastases of stage III melanoma correspond to response and survival in nine patients treated with ipilimumab at the time of stage IV disease

verfasst von: Stefan Diem, Omar Hasan Ali, Christoph J. Ackermann, David Bomze, Viktor H. Koelzer, Wolfram Jochum, Daniel E. Speiser, Kirsten D. Mertz, Lukas Flatz

Erschienen in: Cancer Immunology, Immunotherapy | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Abstract

Prognosis of metastatic melanoma improved with the development of checkpoint inhibitors. The role of tumor infiltrating lymphocytes (TILs) in lymph node metastases of stage III melanoma remains unclear. We retrospectively characterized TILs in primary melanomas and matched lymph node metastases (stage III melanoma) of patients treated with the checkpoint inhibitor ipilimumab. Tumor infiltrating lymphocytes were characterized for CD3, CD4, and CD8 expressions by immunohistochemistry. 4/9 patients (44%) responded to treatment with ipilimumab (1 complete and 2 partial remissions, 1 stable disease). All responders exhibited CD4 and CD8 T-cell infiltration in their lymph node metastases, whereas all non-responders did not show an infiltration of the lymph node metastasis with TILs. The correlation between the presence and absence of TILs in responders vs. non-responders was statistically significant (p = 0.008). Median distant metastases free survival, i.e., progression from stage III to stage IV melanoma, was similar in responders and non-responders (22.1 vs. 19.3 months; p = 0.462). Median progression free and overall survival show a trend in favor of the patients having TIL rich lymph node metastases (6.8 vs. 3.3 months, p = 0.09; and all alive at last follow-up vs. 8.2 months, respectively, p = 0.08). Our data suggest a correlation between the T-cell infiltration of the lymph node metastases in stage III melanoma and the response to ipilimumab once these patients progress to stage IV disease.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
3.
Zurück zum Zitat Weber JS, D’Angelo SP, Minor D et al (2015) Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 16(4):375–384. doi:10.1016/S1470-2045(15)70076-8 CrossRefPubMed Weber JS, D’Angelo SP, Minor D et al (2015) Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 16(4):375–384. doi:10.​1016/​S1470-2045(15)70076-8 CrossRefPubMed
6.
Zurück zum Zitat Ribas A, Puzanov I, Dummer R et al (2015) Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol 16(8):908–918. doi:10.1016/S1470-2045(15)00083-2 CrossRefPubMed Ribas A, Puzanov I, Dummer R et al (2015) Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol 16(8):908–918. doi:10.​1016/​S1470-2045(15)00083-2 CrossRefPubMed
8.
Zurück zum Zitat Oble DA, Loewe R, Yu P et al (2009) Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human melanoma. Cancer Immun 9:3PubMedPubMedCentral Oble DA, Loewe R, Yu P et al (2009) Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human melanoma. Cancer Immun 9:3PubMedPubMedCentral
9.
Zurück zum Zitat Clark WH Jr, Elder DE, Dt Guerry et al (1989) Model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst 81(24):1893–1904CrossRefPubMed Clark WH Jr, Elder DE, Dt Guerry et al (1989) Model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst 81(24):1893–1904CrossRefPubMed
11.
Zurück zum Zitat Mackensen A, Ferradini L, Carcelain G et al (1993) Evidence for in situ amplification of cytotoxic T-lymphocytes with antitumor activity in a human regressive melanoma. Cancer Res 53(15):3569–3573PubMed Mackensen A, Ferradini L, Carcelain G et al (1993) Evidence for in situ amplification of cytotoxic T-lymphocytes with antitumor activity in a human regressive melanoma. Cancer Res 53(15):3569–3573PubMed
12.
Zurück zum Zitat Tefany FJ, Barnetson RS, Halliday GM et al (1991) Immunocytochemical analysis of the cellular infiltrate in primary regressing and non-regressing malignant melanoma. J Invest Dermatol 97(2):197–202CrossRefPubMed Tefany FJ, Barnetson RS, Halliday GM et al (1991) Immunocytochemical analysis of the cellular infiltrate in primary regressing and non-regressing malignant melanoma. J Invest Dermatol 97(2):197–202CrossRefPubMed
16.
Zurück zum Zitat Mohos A, Sebestyen T, Liszkay G et al (2013) Immune cell profile of sentinel lymph nodes in patients with malignant melanoma - FOXP3 + cell density in cases with positive sentinel node status is associated with unfavorable clinical outcome. J Transl Med 11:43. doi:10.1186/1479-5876-11-43 CrossRefPubMedPubMedCentral Mohos A, Sebestyen T, Liszkay G et al (2013) Immune cell profile of sentinel lymph nodes in patients with malignant melanoma - FOXP3 + cell density in cases with positive sentinel node status is associated with unfavorable clinical outcome. J Transl Med 11:43. doi:10.​1186/​1479-5876-11-43 CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Vallacchi V, Vergani E, Camisaschi C et al (2014) Transcriptional profiling of melanoma sentinel nodes identify patients with poor outcome and reveal an association of CD30(+) T lymphocytes with progression. Cancer Res 74(1):130–140. doi:10.1158/0008-5472.CAN-13-1672 CrossRefPubMed Vallacchi V, Vergani E, Camisaschi C et al (2014) Transcriptional profiling of melanoma sentinel nodes identify patients with poor outcome and reveal an association of CD30(+) T lymphocytes with progression. Cancer Res 74(1):130–140. doi:10.​1158/​0008-5472.​CAN-13-1672 CrossRefPubMed
22.
Zurück zum Zitat Kelderman S, Heemskerk B, van Tinteren H et al (2014) Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma. Cancer Immunol Immunother 63(5):449–458. doi:10.1007/s00262-014-1528-9 PubMed Kelderman S, Heemskerk B, van Tinteren H et al (2014) Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma. Cancer Immunol Immunother 63(5):449–458. doi:10.​1007/​s00262-014-1528-9 PubMed
25.
Zurück zum Zitat Delyon J, Mateus C, Lefeuvre D et al (2013) Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival. Ann Oncol 24(6):1697–1703. doi:10.1093/annonc/mdt027 CrossRefPubMed Delyon J, Mateus C, Lefeuvre D et al (2013) Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival. Ann Oncol 24(6):1697–1703. doi:10.​1093/​annonc/​mdt027 CrossRefPubMed
Metadaten
Titel
Tumor infiltrating lymphocytes in lymph node metastases of stage III melanoma correspond to response and survival in nine patients treated with ipilimumab at the time of stage IV disease
verfasst von
Stefan Diem
Omar Hasan Ali
Christoph J. Ackermann
David Bomze
Viktor H. Koelzer
Wolfram Jochum
Daniel E. Speiser
Kirsten D. Mertz
Lukas Flatz
Publikationsdatum
11.09.2017
Verlag
Springer Berlin Heidelberg
Erschienen in
Cancer Immunology, Immunotherapy / Ausgabe 1/2018
Print ISSN: 0340-7004
Elektronische ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-017-2061-4

Weitere Artikel der Ausgabe 1/2018

Cancer Immunology, Immunotherapy 1/2018 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.